期刊文献+

慢性阻塞性肺疾病患者吸入用药的药学监护要点 被引量:4

Pharmaceutical Care for Patients with Chronic Obstructive Pulmonary Disease Receiving Inhalants
暂未订购
导出
摘要 目的:对慢性阻塞性肺疾病患者使用吸入药物进行药学监护,提高患者用药依从性及治疗效果。方法:结合治疗方案,指导慢性阻塞性肺疾病患者正确使用吸入药物,从选择药物到评价疗效进行全程药学监护。结果:通过药学监护,患者能够熟练地掌握吸入药物使用技巧,提高了依从性和治疗效果。结论:慢性阻塞性肺疾病患者吸入用药的技巧掌握率低,专业人员的指导对提高疗效和生活质量十分重要,药学监护应成为治疗过程中的一个重要环节。 OBJECTIVE:To provide pharmaceutical care for the patients with chronic obstructive pulmonary disease(COPD) receiving inhalants,improve patients' compliance and curative efficacy.METHODS:With treatment plan as reference,the pharmacists provided guidance for patients regarding the correct use of inhalants and carry out pharmaceutical care throughout treatment course including the choice of medicine and evaluation on curative efficacy.RESULTS:The pharmaceutical care facilitated patients'mastering of the correct administration of inhalants and improved patients' compliance and therapeutic efficacy.CONCLUSION:In view of poor knowledge of patients' on administration of inhalants,pharmacists'professional guidance is of great importance for improvement of curative efficacy and patients' quality of life.Pharmaceutical care should be regarded as one important link in the treatment process.
出处 《中国医院用药评价与分析》 2012年第11期1039-1041,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 慢性阻塞性肺疾病 吸入药物 药学监护 Chronic obstructive pulmonary disease Inhalants Pharmaceutical care
  • 相关文献

参考文献9

二级参考文献47

共引文献1976

同被引文献26

  • 1慢性阻塞性肺疾病诊疗规范(2011年版)[J].中国医学前沿杂志(电子版),2012,4(1):69-76. 被引量:264
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8251
  • 3Vestbo J, Hurd SS, Agusti AG, et al. Glo- bal strategy for the diagnosis, manage- ment, and prevention of chronic obstruc- tive pulmonary disease: GOLD executive summary[J]. Am J Respir Crit Care Med, 2013,187(4):347-365.
  • 4Kew KM, Maveigranes C, Walters JA. Long- acting beta2-agonists for chronic obstruc- tive pulmonary disease[J].Cochrane Data- base Syst Rev, 2013,15(10): 1002-1005.
  • 5Azarisman SM, Hadzri HM, Fauzi RA, et al. Compliance to national guidelines on the management of chronic obstructive pulmonary disease in Malaysia: a single centre experience [J]. Singapore Med J, 2008,49(11):886-891.
  • 6Marc M, Juan J, Mynam C, el al. A hey, approach to gradh,g and treating COPD based on clinical pheuotypes: summary of the Spanish COPD guidelines (GcsEPOC) [ J ]. Prim Carc Respil, 2013, 22(1): 117-121.
  • 7Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theopbylline in the treatment of COPD [ J ]. Chest, 2012, 121(4) : 1058-1069.
  • 8Wang J, Nie B, Xiong W, et al. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis [ J ]. J Clin Pharm Ther, 2012, 37(2) : 204-211.
  • 9Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safetycharac- teristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized 52-week placebo-controlled trials[J]. Int J Chron Obstruct Pulmon Dis, 2012(7) : 73-86.
  • 10Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled ( beta ) 2-agonist indacaterol versus twice-daily formoterol in COPD[J]. Thorax, 2010, 65(6) : 473-479.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部